Health Robotics continues to lead the global healthcare industry and persisting on its worldwide quest to pervasively provide safe and cost-effective Intravenous Admixture Compounding Automation to hospitals all over the world.
Byung Ahn, Dongbang Healthdyne' President, stated: “Following the dramatic increase in life expectancy of the Korean population, we have recently experienced a three-fold increase of cancer patients in our country. Compounding Oncology IV preparations is rapidly becoming a large unsolved issue for Korean hospitals. Our market research shows very prosperous business projections for Health Robotics, especially for its 2nd Generation i.v.STATION ONCO, as Korean pharmacists look forward to replace with Robots this “low-level” work [legally part of their duties], and in my opinion, they are not going to accept the old technology alternatives1.”
Gaspar DeViedma, Health Robotics' Executive Vice President, stated: “i.v.STATION ONCO represents Health Robotics' 2nd Generation Cancer Therapy Compounding robot for syringes and I.V. Bags, introduced into the global healthcare market well before any of our competitors[1] can even prove their fictional 20+ year old[2] claims at any hospital in the world. Amongst the technology innovations pioneered by i.v.STATION ONCO are its: ability to handle pre-attached lines to IV Bags; small footprint [at 15% to 25% of the size/weight of other IV Robots]; faster throughput [up to 40 doses per hour instead of 20 doses per hour]; automated tamper-evident syringe capping; and finally, RFID support. Together with i.v.STATION and i.v.SOFT, we expect i.v.STATION ONCO to dominate the Korean market.”
Byung Ahn, Dongbang Healthdyne' President, stated: “Following the dramatic increase in life expectancy of the Korean population, we have recently experienced a three-fold increase of cancer patients in our country. Compounding Oncology IV preparations is rapidly becoming a large unsolved issue for Korean hospitals. Our market research shows very prosperous business projections for Health Robotics, especially for its 2nd Generation i.v.STATION ONCO, as Korean pharmacists look forward to replace with Robots this “low-level” work [legally part of their duties], and in my opinion, they are not going to accept the old technology alternatives1.”
Gaspar DeViedma, Health Robotics' Executive Vice President, stated: “i.v.STATION ONCO represents Health Robotics' 2nd Generation Cancer Therapy Compounding robot for syringes and I.V. Bags, introduced into the global healthcare market well before any of our competitors[1] can even prove their fictional 20+ year old[2] claims at any hospital in the world. Amongst the technology innovations pioneered by i.v.STATION ONCO are its: ability to handle pre-attached lines to IV Bags; small footprint [at 15% to 25% of the size/weight of other IV Robots]; faster throughput [up to 40 doses per hour instead of 20 doses per hour]; automated tamper-evident syringe capping; and finally, RFID support. Together with i.v.STATION and i.v.SOFT, we expect i.v.STATION ONCO to dominate the Korean market.”
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
